U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C15H20N2O2
Molecular Weight 260.3315
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENSPIRIDE

SMILES

O=C1NCC2(CCN(CCC3=CC=CC=C3)CC2)O1

InChI

InChIKey=FVNFBBAOMBJTST-UHFFFAOYSA-N
InChI=1S/C15H20N2O2/c18-14-16-12-15(19-14)7-10-17(11-8-15)9-6-13-4-2-1-3-5-13/h1-5H,6-12H2,(H,16,18)

HIDE SMILES / InChI

Molecular Formula C15H20N2O2
Molecular Weight 260.3315
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Fenspiride is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases. It is approved for use in Russia for the treatment of acute and chronic inflammatory diseases of ENT organs and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as for maintenance treatment of asthma. Fenspiride is marketed under the brand names Eurespal, Pneumorel, SYRESP, Oxofen and others. Erespal (fenspiride) is a drug with a bronchodilator and spasmolytic effect, which is often used in the complex therapy of bronchial asthma. Fenspiride has a clinically proven ability to increase the activity of the cilia of the bronchial ciliated epithelium, normalize the secretion of the bronchi and reduce its viscosity. Effectively removes bronchial obstruction, restores pulmonary gas exchange. Inhibits the metabolism of arachidonic acid, in parallel blocking histamine H1-receptors, since it is histamine that stimulates the chemical reactions of the transformation of arachidonic acid into the final metabolites-factors of inflammation. Reduces the production of other mediators of inflammation - serotonin and bradykinin. It blocks α-adrenergic receptors, the activation of which increases the secretion of bronchial glands. The complex effect of fenspiride reduces the pathological effect of a number of factors that promote hypersecretion of anti-inflammatory substances and cause obstruction of the bronchial tree. Has a pronounced antispasmodic and myotropic effect.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P16599
Gene ID: 103694380|||24835
Gene Symbol: Tnf
Target Organism: Rattus norvegicus (Rat)
4.16 null [pIC50]
3.44 null [pIC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Erespal

Approved Use

The drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions): pharyngitis; Rhinopharyngitis; laryngitis; tracheitis; Tracheobronchitis; Bronchitis (with or without chronic respiratory failure); bronchial asthma; Respiratory symptoms with influenza, measles and whooping cough; sinusitis; otitis; Infection of the respiratory system, in the symptomatic complex of which there is a cough.
Primary
Erespal

Approved Use

The drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions): pharyngitis; Rhinopharyngitis; laryngitis; tracheitis; Tracheobronchitis; Bronchitis (with or without chronic respiratory failure); bronchial asthma; Respiratory symptoms with influenza, measles and whooping cough; sinusitis; otitis; Infection of the respiratory system, in the symptomatic complex of which there is a cough.
Primary
Erespal

Approved Use

The drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions): pharyngitis; Rhinopharyngitis; laryngitis; tracheitis; Tracheobronchitis; Bronchitis (with or without chronic respiratory failure); bronchial asthma; Respiratory symptoms with influenza, measles and whooping cough; sinusitis; otitis; Infection of the respiratory system, in the symptomatic complex of which there is a cough.
Primary
Erespal

Approved Use

The drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions): pharyngitis; Rhinopharyngitis; laryngitis; tracheitis; Tracheobronchitis; Bronchitis (with or without chronic respiratory failure); bronchial asthma; Respiratory symptoms with influenza, measles and whooping cough; sinusitis; otitis; Infection of the respiratory system, in the symptomatic complex of which there is a cough.
Primary
Eurespal

Approved Use

Indications: Rinofaringitis, laryngitis — otitis, sinusitis — rinotraheobronhit — bronchitis — bronchial asthma (maintenance therapy) respiratory effects in measles, pertussis and influenza (syrup).
Primary
Eurespal

Approved Use

Indications: Rinofaringitis, laryngitis — otitis, sinusitis — rinotraheobronhit — bronchitis — bronchial asthma (maintenance therapy) respiratory effects in measles, pertussis and influenza (syrup).
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
206 ng/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENSPIRIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
329.35 ng/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENSPIRIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
381.58 ng/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENSPIRIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
1034.09 ng/mL
80 mg 2 times / day multiple, oral
dose: 80 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FENSPIRIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6.03 μg × h/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENSPIRIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.73 μg × h/mL
80 mg single, intravenous
dose: 80 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FENSPIRIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10259.9 ng × h/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENSPIRIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9576.89 ng × h/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENSPIRIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
11208.73 ng × h/mL
80 mg 2 times / day multiple, oral
dose: 80 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FENSPIRIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
16 h
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENSPIRIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
14 h
80 mg single, intravenous
dose: 80 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FENSPIRIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
80 mg 2 times / day multiple, oral
Recommended
Dose: 80 mg, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Disc. AE: Allergy...
AEs leading to
discontinuation/dose reduction:
Allergy (4%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Allergy 4%
Disc. AE
80 mg 2 times / day multiple, oral
Recommended
Dose: 80 mg, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
[Bronchial inflammation during chronic bronchitis, importance of fenspiride].
2002 Sep
[Fenspiride-a new alternative on the therapy of obstructive lung disease].
2003 Apr-Jun
[Effectiveness and tolerance of fenspiride treatment in chronic sinusitis. Results of the Polish multicenter study].
2005
[The effect of fenspiride on the number of exacerbations and the time of first exacerbation in patients with chronic bronchitis].
2005 Aug
[Usefulness of fenspiride in the treatment of acute otitis media in children].
2005 Jun
Comparison of fenspiride with beclomethasone as adjunctive anti-inflammatory treatment in patients with chronic obstructive pulmonary disease.
2006
[Erespal in combined therapy of acute rhinosinusitis].
2006
[New pharmaceuticals in treatment of chronic dust bronchitis].
2007
[The effectiveness of fenspiride in the treatment of patients with chronic obstructive pulmonary disease].
2007
[Clinicofunctional condition and quality of life in patients with chronic obstructive pulmonary disease before and after outpatient treatment with fenspiride].
2008
Patents

Sample Use Guides

Tablets: One tablet (80 mg) twice-thrice a day. The maximum dose for a daily intake is 240 mg (3 tablets).Syrup: For 45-90 milliliters (3-6 tablespoons, respectively) per day.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Fenspiride (10(-7)-10(-5) M) inhibited the histamine H1 receptor-induced Ca2+ increase in a lung epithelial cell line. Fenspiride (10(-5) M) abolished both phases of histamine-induced arachidonic acid release. https://www.ncbi.nlm.nih.gov/pubmed/9652346
Fenspiride (10(-6) to 10(-4) M) inhibited the nonadrenergic, noncholinergic (NANC) component of the contraction of the guinea-pig isolated main bronchus induced by EFS. Fenspiride significantly affected contractions induced by exogenously added substance P or [Nle10]-NKA(4-10) only at concentrations higher than 10(-3) M. In the guinea-pig perfused lung, fenspiride inhibited low pH- but not capsaicin-evoked release of CGRP. At higher concentrations (10(-4) M to 3x10(-4) M) fenspiride exhibited a significant inhibitory effect both on the cholinergic component of contractile response induced by EFS in the guinea-pig isolated main bronchus and on exogenously added acetylcholine.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:11:13 GMT 2025
Edited
by admin
on Mon Mar 31 18:11:13 GMT 2025
Record UNII
S983QC7HKM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FENSPIRIDE
INN   MI   WHO-DD  
INN  
Official Name English
EURESPAL
Preferred Name English
1-OXA-3,8-DIAZASPIRO(4,5)DECAN-2-ONE, 8-(2-PHENYLETHYL)-
Systematic Name English
fenspiride [INN]
Common Name English
8-PHENETHYL-1-OXA-3,8-DIAZASPIRO(4.5)DECAN-2-ONE
Systematic Name English
Fenspiride [WHO-DD]
Common Name English
FENSPIRIDE [MI]
Common Name English
Classification Tree Code System Code
WHO-VATC QR03BX01
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
NCI_THESAURUS C29707
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
WHO-ATC R03BX01
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
WHO-VATC QR03DX03
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
WHO-ATC R03DX03
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL576127
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
PRIMARY
EPA CompTox
DTXSID4023048
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
PRIMARY
SMS_ID
100000081488
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
PRIMARY
CAS
5053-06-5
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
PRIMARY
PUBCHEM
3344
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
PRIMARY
EVMPD
SUB07596MIG
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
PRIMARY
DRUG CENTRAL
1163
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
PRIMARY
WIKIPEDIA
FENSPIRIDE
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
PRIMARY
DRUG BANK
DB08979
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
PRIMARY
INN
2577
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
PRIMARY
MERCK INDEX
m5296
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
PRIMARY Merck Index
NCI_THESAURUS
C80880
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
PRIMARY
RXCUI
4335
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
PRIMARY RxNorm
MESH
C084775
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
PRIMARY
ECHA (EC/EINECS)
225-751-3
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
PRIMARY
FDA UNII
S983QC7HKM
Created by admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY